Attached files

file filename
EX-10.4 - EXHIBIT 10.4 - Kite Pharma, Inc.kite20161231ex104.htm
EX-32.1 - EXHIBIT 32.1 - Kite Pharma, Inc.kite20161231ex321.htm
EX-31.2 - EXHIBIT 31.2 - Kite Pharma, Inc.kite20161231ex312.htm
EX-31.1 - EXHIBIT 31.1 - Kite Pharma, Inc.kite20161231ex311.htm
EX-23.1 - EXHIBIT 23.1 - Kite Pharma, Inc.kite20161231ex231.htm
EX-21.1 - EXHIBIT 21.1 - Kite Pharma, Inc.kite20161231ex211.htm
EX-10.5 - EXHIBIT 10.5 - Kite Pharma, Inc.kite20161231ex105.htm
EX-10.3 - EXHIBIT 10.3 - Kite Pharma, Inc.kite20161231ex103.htm
10-K - 10-K - Kite Pharma, Inc.kite20161231-10k.htm


Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Kite Pharma, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul L. Jenkinson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
By:    /s/ Paul L. Jenkinson            
Name: Paul L. Jenkinson
Title: Chief Financial Officer

Date: February 28, 2017
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate document.